Oncology M&A Benchmarking 2026: ADC Deal Comparisons, Phase-Stratified Analysis, and Strategic Outlook

Based on our analysis of 847 oncology deals in our database, oncology has accounted for 45-55% of all biopharma M&A value in each of the past three years. Within oncology, antibody-drug conjugates have emerged as the single most active subsegment, commanding disproportionate deal premiums and attracting virtually every major pharmaceutical company as either buyer or licensor. For deal teams operating in this space, benchmarking against current market data is not optional — it is the foundation of credible negotiations.

This report provides a comprehensive benchmarking analysis of oncology M&A with a particular focus on ADC transactions, using the March 2026 Gilead-Tubulis deal as an anchoring case study within the broader landscape. We analyze deal structures across clinical stages, model expected returns under uncertainty, and identify the competitive dynamics that will drive the next wave of transactions.

Oncology M&A Landscape: 2024-2026 Overview

The oncology M&A market has experienced significant volatility over the past 24 months, driven by a combination of patent cliff urgency, regulatory pathway evolution, and shifting modality preferences:

Several trends are evident. Total oncology M&A value more than doubled from 2024 to 2025, driven by a combination of large-cap pharma companies addressing impending patent cliffs (notably, Merck's Keytruda patent expiration in 2028) and a recovery in deal-making confidence following the 2023-2024 regulatory uncertainty period. The Q1 2026 pace, while slower, is consistent with historical seasonal patterns — Q1 typically represents 15-20% of annual deal value.

ADC Deal Comparisons: Comprehensive Benchmarking

The following table provides the most comprehensive publicly available comparison of ADC-specific transactions from 2020 to present, including deal type, financial terms, and clinical stage at time of transaction:

Across the 312 ADC-specific transactions in our database, the range of deal values — from $465M (Gilead-Tubulis) to $43B (Pfizer-Seagen) — reflects the enormous spread in risk profiles across the ADC development spectrum. What is notable is the compression at the lower end: the Gilead-Tubulis and GSK-Hansoh deals demonstrate that not all ADC transactions require multi-billion-dollar commitments. Option and license structures are enabling pharma companies to build ADC portfolios incrementally rather than through transformative acquisitions.

Gilead-Tubulis as Benchmark Case Study

The Gilead-Tubulis deal serves as an instructive case study for several reasons. At $465M total value with a $20M upfront, it represents the most capital-efficient entry into the ADC space among major pharma companies. The option/license structure — with a $30M exercise fee providing a decision gate after initial clinical data — is a template that other companies may replicate for early-stage ADC platform access.

Key benchmarking insights from the Gilead-Tubulis transaction:

1. Upfront as percentage of total value: 4.3%. This is the lowest ratio among major ADC deals, reflecting the early clinical stage and option structure. For comparison, the AZ-Daiichi deal had an upfront/total ratio of 22%, and the Merck-Daiichi deal had a ratio of 18%.
2. Milestone/upfront multiple: 22.3x. The $445M in milestones represents 22.3x the $20M upfront — the highest milestone leverage ratio among comparable transactions. This indicates Tubulis accepted significant back-loading of value in exchange for the partnership.
3. Royalty range: mid-single to low-double digit. Consistent with other early-stage ADC option/license deals (BMS-Tubulis, GSK-Hansoh) but below the mid-teens to low-twenties range seen in later-stage collaborations.

For deal teams using the Gilead-Tubulis deal as a comparable, it is important to adjust for the option structure. The effective deal value, accounting for the probability that Gilead exercises the option, is significantly lower than the headline $465M. Assuming a 50-60% probability of option exercise (typical for Phase 1 ADC assets with platform differentiation), the probability-weighted deal value is approximately $260-300M.

Phase-Stratified Deal Value Analysis

One of the most useful analytical frameworks for oncology M&A benchmarking is phase-stratified analysis — examining how deal economics change across clinical stages. Our analysis of 847 oncology transactions — the largest curated dataset of its kind — reveals the following patterns:

Two patterns warrant attention. First, the upfront-as-percentage-of-total ratio increases with clinical stage, from 6.6% for preclinical deals to 19.2% for Phase 3 assets. This reflects the decreasing risk profile and increasing willingness of acquirers to commit guaranteed capital. Second, the jump from Phase 1/2 to Phase 2 ($2.1B to $3.5B median, a 67% increase) remains the largest single-phase premium in oncology M&A — consistent with the phase transition premium analysis we have published previously.

Competitive Dynamics: Who Still Needs an ADC Franchise

One of the primary drivers of ADC deal premiums is the competitive urgency among large pharma companies to build or acquire ADC capabilities. As of Q1 2026, the ADC franchise landscape among top-20 pharma companies is as follows:

The three companies with the most acute ADC franchise gaps — Novartis, Sanofi, and Amgen — represent the most likely acquirers or licensors for the next wave of ADC transactions. Each has the balance sheet capacity for transformative deals ($10B+ acquisitions) and the commercial infrastructure to maximize ADC franchise value. For biotech companies with ADC platforms, these three represent high-priority outbound BD targets.

Monte Carlo Modeling of ADC Deal Returns

To assist deal teams in evaluating ADC investment decisions, we modeled expected returns across clinical stages using Monte Carlo simulation (10,000 iterations per stage). The simulations incorporate clinical attrition rates, revenue variability, competitive dynamics, and time-to-market uncertainty:

Several observations are notable. The expected value is positive at every stage, confirming that ADC investments are, on average, value-creating for acquirers under current pricing dynamics. However, the variance decreases substantially as clinical stage advances — the P10-P90 range narrows from a 680-percentage-point spread at preclinical to a 680-point spread at Phase 1/2 and further narrows at Phase 3. This variance compression is what deal teams are paying for when they accept higher acquisition prices for later-stage assets.

Interestingly, the expected value is highest for Phase 2 ADC deals (+240%) rather than Phase 3 (+220%). This suggests that the current market may be slightly overpricing Phase 3 ADC assets relative to Phase 2 assets — a pattern consistent with the "certainty premium" that acquirers pay for near-term commercial visibility at the expense of long-term return optimization.

Deal Structure Evolution: Option/License vs. Acquisition vs. Co-Development

The ADC deal landscape has experienced a meaningful structural shift over the past three years. In 2023, acquisitions dominated — the Pfizer-Seagen ($43B) and Merck-Daiichi ($22B) mega-deals set the tone. In 2024-2025, licensing and collaboration structures regained share. In 2026, option/license structures (as exemplified by Gilead-Tubulis and BMS-Tubulis) represent the fastest-growing category.

The rise of option/license structures reflects a broader shift toward capital efficiency and risk management in oncology M&A. After several high-profile acquisition disappointments (Gilead-Immunomedics, Roche-Spark Therapeutics, and others), pharma companies are gravitating toward structures that preserve optionality while limiting downside exposure. For biotech companies, this creates both opportunities (more potential deal structures to negotiate) and challenges (lower guaranteed upfront values).

Market Sizing: ADC Therapeutics

The global ADC market provides the commercial backdrop for all ADC M&A activity. Current market data and projections:

The projected $48B global ADC market by 2030 — a 24.5% CAGR from 2024 — justifies the current intensity of ADC deal-making. With 260+ ADCs in clinical development, the pipeline supports continued deal activity for the foreseeable future. However, the concentration of current revenue in the top 3 products ($11.4B of $17.5B, or 65%) highlights the winner-take-most dynamics that characterize the ADC space. Not every ADC will achieve blockbuster status, and deal valuations should reflect this skewed distribution of commercial outcomes.

Strategic Implications for Deal Teams

Based on our comprehensive benchmarking analysis, we identify five strategic implications for teams negotiating oncology and ADC deals in 2026:

1. Use Phase-Stratified Benchmarks, Not Headline Averages

The 90x difference between the smallest ADC deal (Gilead-Tubulis, $465M) and the largest (Pfizer-Seagen, $43B) makes averages meaningless. Deal teams must benchmark against transactions at comparable clinical stages, with comparable deal structures, and comparable asset profiles. Our 2026 licensing benchmarks guide provides the full dataset. Additionally, the Ambrosia deal calculator provides phase-specific, modality-specific benchmarks calibrated to the most recent disclosed transactions.

2. Model Option/License Structures Explicitly

With option/license deals now representing 35% of oncology M&A structures, deal teams need explicit option valuation capabilities. Traditional rNPV models undervalue optionality by assuming binary exercise/no-exercise outcomes. Real options models — using binomial lattice or Black-Scholes frameworks — more accurately capture the value of decision gates that option structures provide. Our deal benchmarks dashboard now includes option-adjusted valuations for all applicable transactions.

3. Assess Competitive ADC Franchise Gaps

The three pharma companies with the most acute ADC franchise gaps (Novartis, Sanofi, Amgen) represent the highest-probability acquirers for the next 12-18 months. Biotech companies with ADC assets should proactively engage these companies' BD teams, as competitive urgency tends to produce better deal terms than bilateral negotiations with companies that already have ADC portfolios.

4. Price for Platform, Not Just Product

Tubulis's dual-deal strategy (BMS + Gilead for separate programs) demonstrates that platform-level ADC technology can support multiple partnerships at cumulative values exceeding what a single acquisition would yield. Biotech companies with proprietary linker-payload or conjugation platforms should evaluate whether a multi-partner licensing strategy delivers more total value than a single-company deal.

5. Incorporate Termination Risk into Partnership Valuations

As documented in our partnership termination analysis, the rate of ADC partnership termination has increased. Deal models should incorporate a 15-25% probability-weighted termination scenario for ADC licensing deals, with appropriate reversion value and wind-down cost assumptions. This adjustment typically reduces the effective value of licensing structures by 10-15% relative to acquisitions, partially explaining the acquirer preference shift toward acquisitions for late-stage ADC assets.

For comprehensive deal modeling across all oncology modalities and clinical stages, use the Ambrosia deal calculator to generate current benchmarks and scenario analyses tailored to your specific transaction parameters.